BioCentury
ARTICLE | Clinical News

AKB-9778: Additional Phase Ib/IIa data

March 16, 2015 7:00 AM UTC

Additional data from the open-label, dose-escalation, U.S. Phase Ib/IIa TIME-1 trial in 18 evaluable patients with DME showed that twice-daily subcutaneous AKB-9778 at doses of >=15 mg for 28 days imp...